EP0900086A4 - Stimulation du sommeil avec un secretagogue d'hormone de croissance - Google Patents

Stimulation du sommeil avec un secretagogue d'hormone de croissance

Info

Publication number
EP0900086A4
EP0900086A4 EP97924576A EP97924576A EP0900086A4 EP 0900086 A4 EP0900086 A4 EP 0900086A4 EP 97924576 A EP97924576 A EP 97924576A EP 97924576 A EP97924576 A EP 97924576A EP 0900086 A4 EP0900086 A4 EP 0900086A4
Authority
EP
European Patent Office
Prior art keywords
sleep
enhancement
growth hormone
hormone secretagogue
secretagogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97924576A
Other languages
German (de)
English (en)
Other versions
EP0900086A1 (fr
Inventor
Joanne Waldstreicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611002.8A external-priority patent/GB9611002D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0900086A1 publication Critical patent/EP0900086A1/fr
Publication of EP0900086A4 publication Critical patent/EP0900086A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP97924576A 1996-05-07 1997-05-05 Stimulation du sommeil avec un secretagogue d'hormone de croissance Withdrawn EP0900086A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1678796P 1996-05-07 1996-05-07
US16787P 1996-05-07
GB9611002 1996-05-24
GBGB9611002.8A GB9611002D0 (en) 1996-05-24 1996-05-24 Enhancement of sleep with a growth hormone secreragogue
PCT/US1997/007516 WO1997041879A1 (fr) 1996-05-07 1997-05-05 Stimulation du sommeil avec un secretagogue d'hormone de croissance

Publications (2)

Publication Number Publication Date
EP0900086A1 EP0900086A1 (fr) 1999-03-10
EP0900086A4 true EP0900086A4 (fr) 2000-01-12

Family

ID=26309399

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97924576A Withdrawn EP0900086A4 (fr) 1996-05-07 1997-05-05 Stimulation du sommeil avec un secretagogue d'hormone de croissance

Country Status (5)

Country Link
EP (1) EP0900086A4 (fr)
JP (1) JP2000511885A (fr)
AU (1) AU711884B2 (fr)
CA (1) CA2253390A1 (fr)
WO (1) WO1997041879A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3220097A (en) 1996-05-22 1997-12-09 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL144468A0 (en) * 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
JP4731031B2 (ja) * 2001-03-30 2011-07-20 株式会社デンソー 睡眠解析装置及びプログラム並びに記録媒体
JP2006520371A (ja) * 2003-03-14 2006-09-07 メルク　シャープ　エンド　ドーム　リミテッド 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法
WO2004108120A1 (fr) * 2003-06-11 2004-12-16 Pfizer Products Inc. Utilisation de sécrétagogues de l'hormone de croissance pour le traitement de la fibromyalgie
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP2374455A3 (fr) 2004-08-19 2012-03-28 Vertex Pharmaceuticals Incorporated Modulateurs des recepteurs muscariniques
RU2007124373A (ru) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
RU2008130094A (ru) 2005-12-22 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
WO2007100670A1 (fr) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulateurs des recepteurs muscariniques
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2040706A2 (fr) 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulateurs des récepteurs muscariniques
JP2010500412A (ja) 2006-08-15 2010-01-07 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
CN101573121A (zh) 2006-08-18 2009-11-04 弗特克斯药品有限公司 毒蕈碱受体调节剂
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
WO2009045519A1 (fr) 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulateurs des récepteurs muscariniques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (fr) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidines et ses homologues favorisants la libération de l'hormone de croissance.
WO1996040105A1 (fr) * 1995-06-07 1996-12-19 Arch Development Corporation UTILISATION DE η-HYDROXYBUTYRATE POUR STIMULER LA SECRETION DE L'HORMONE DE CROISSANCE ASSOCIEE AU SOMMEIL
WO1997034604A1 (fr) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines favorisant la liberation de l'hormone de croissance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0662481A1 (fr) * 1992-12-11 1995-07-12 Merck & Co. Inc. Spiro piperidines et ses homologues favorisants la libération de l'hormone de croissance.
WO1996040105A1 (fr) * 1995-06-07 1996-12-19 Arch Development Corporation UTILISATION DE η-HYDROXYBUTYRATE POUR STIMULER LA SECRETION DE L'HORMONE DE CROISSANCE ASSOCIEE AU SOMMEIL
WO1997034604A1 (fr) * 1996-03-21 1997-09-25 Merck & Co., Inc. 4-spiroindoline piperidines favorisant la liberation de l'hormone de croissance

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 1994, 1994, Philadelphia, PA, US; abstract no. 75188, M L HARTMAN ET AL.: "Normal control of growth hormone secretion" XP002122541 *
DATABASE MEDLINE 1 January 1900 (1900-01-01), XP002122540, Database accession no. 96320058 *
G COPINSCHI ET AL.: "Effects of a 7-day treatment with a novel, orally active, growth hormone secretagogue, MK-677,on 24-hour GH profiles, insulin-like growth factor I, amd adrenocortical function in normal young men", J. CLIN. ENDOCRINOL. METABOLISM, vol. 81, no. 8, August 1996 (1996-08-01), pages 2776 - 2782 *
HORMONE RESEARCH, vol. 40, no. 1-3, 1993, Basel, pages 37 - 47 *
J TAKAHARA ET AL.: "Inhibitory effects of substance P on the gamma-aminobutyric acid and gamma-hydroxybutyric acid-induced growth hormone and prolactin release in male rats", LIFE SCIENCES, vol. 29, no. 12, 1981, UK, pages 1229 - 1233, XP000600046 *
J TAKAHARA ET AL.: "Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans", J CLIN. ENDOCRIN. METAB., vol. 44, no. 5, 1977, USA, pages 1014 - 1017, XP000600031 *
M MAMELAK ET AL.: "The effects of gamma-hydroxybutyrate on sleep", BIOLOGICAL PSYCHIATRY, vol. 12, no. 2, 1977, USA, pages 273 - 288, XP000600034 *
See also references of WO9741879A1 *

Also Published As

Publication number Publication date
AU711884B2 (en) 1999-10-21
WO1997041879A1 (fr) 1997-11-13
CA2253390A1 (fr) 1997-11-13
EP0900086A1 (fr) 1999-03-10
AU2996397A (en) 1997-11-26
JP2000511885A (ja) 2000-09-12

Similar Documents

Publication Publication Date Title
EP0900086A4 (fr) Stimulation du sommeil avec un secretagogue d'hormone de croissance
AU3220097A (en) Sleep quality improvement using a growth hormone secretagogue
AU2931997A (en) Treatment of mood disorders with a growth hormone secretagogue
EP0741578A4 (fr) Hormone de croissance humaine
PL314003A1 (en) Combination of bisulphonates and substances enhancing secretion of growth hormone
IL134596A0 (en) Growth hormone secretagogues
ZA968989B (en) Polymorphic forms of a growth hormone secretagogue
EP0785784A4 (fr) Piperidines heterocycliques en position 4 favorisant la liberation de l'hormone de croissance
EP0726901A4 (fr) Macrocycles benzo-condenses stimulant la liberation de l'hormone de croissance
IL156465A0 (en) Treatment of insulin resistance with growth hormone secretagogues
HU9701277D0 (en) Process for producing parathiroide mormone-analogous and peptides connected with parathiroide hormone
GB9622440D0 (en) Treatment of congestive heart failure with a growth hormone secretagogue
IL133043A0 (en) Process and intermediates for growth hormone secretagogues
GB9616700D0 (en) Hormone supplement
GB9611002D0 (en) Enhancement of sleep with a growth hormone secreragogue
HK1017894A1 (en) Polymorphic forms of a growth hormone secretagogue
GB9603834D0 (en) Amorphous form of a growth hormone secretagogue
GB9609696D0 (en) Treatment of congestive heart failure with a growth hormone secretagogue
GB9614941D0 (en) Treatment of mood disorders with a growth hormone secretagogue
EP1112071A4 (fr) Secretagogues d'hormones de croissance
SI0935469T1 (en) Use of growth hormone
GB9603361D0 (en) Polymorphic forms of a growth hormone secretagogue
GB9602949D0 (en) Process for the preparation of a growth hormone secretagogue
AU2419097A (en) Use of growth hormone
GB9625815D0 (en) Convergent process for the preparation of a growth hormone secretagogue

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991129

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000620

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010102